ESC Premium Access

The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Congress Presentation

About the speaker

Mrs Oksana Obertynska

National Pirogov Memorial Medical University, Vinnitsa (Ukraine)
0 follower

5 more presentations in this session

Effect of Dapagliflozin on health-related quality of life in patients with heart failure: a meta-analysis of Randomized Controlled Trials

Speaker: Mrs M. De Souza (Curitiba, BR)

Thumbnail

Disparities in SGLT2i utilization among heart failure patients with different ejection fraction in China: findings from chinese cardiovascular association database-heart failure center registry

Speaker: Mr Q. Zhang (Beijing, CN)

Thumbnail

Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure

Speaker: Mr A. Hacil (Paris, FR) Professor O. Hanon (Paris, FR)

Thumbnail

Impact of dapagliflozin on supraventricular and ventricular arrhythmias, assessed by Holter ECG, in patients with heart failure with reduced ejection fraction

Speaker: Professor A. Abdellah (Ismailia, EG)

Thumbnail

Beneficial effects of the SGLT2 inhibition on oxidative skeletal muscle in infarcted rats

Speaker: Miss L. Souza (Botucatu, BR)

Thumbnail

Access the full session

Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

Speakers: Mrs O. Obertynska, Mrs M. De Souza, Mr Q. Zhang, Mr A. Hacil, Professor O. Hanon...
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations